We invite you to join the quarterly board of directors meeting for the National Hemophilia Foundation on December 2nd starting at 7:00 pm ET. This meeting will discuss NHF business operations and decisions and…
Historically, data on infants and toddlers (ITs) with von Willebrand disease (VWD), particularly relevant to bleeding patterns, has been lacking. To address this absence of data, a team of researchers from the U.S. Hemophilia Treatment Center…
Sigilon Therapeutics today reported a new development in the company’s phase 1/2 clinical study of SIG-001 in individuals with severe or moderately severe hemophilia. This follows the events of this past summer when the U.S. Food and Drug…
NHF’s Washington Days is an opportunity for people affected by inherited blood disorders to advocate for issues that are important to them. In 2021, Washington Days had more than 400 volunteer advocates from 45 states that met with legislators and…
PRESS RELEASE
FOR IMMEDIATE RELEASE
MEDIA CONTACT:
Ilana Ostrin
212-328-3769
iostrin@hemophilia.org
NHF’s newest scholarship honors future leaders, advocates, and…
Pase las tardes de los Martes con el equipo de Educación para el Empoderamiento de NHF. A lo largo de las próximas cuatro semanas, presentaremos talleres de nuestras nuevas series educativas, que abarcan una gran variedad de temas. Cada serie…
Pain assessment and treatment in bleeding disorder care: The need for social work specific education
Objective:
Persons with bleeding disorders experience pain in association with needle pokes, joint and muscle bleeds and permanent tissue damage. The impact of this pain on patients can include time off school or work, a…
Pase las tardes de los Martes con el equipo de Educación para el Empoderamiento de NHF. A lo largo de las próximas cuatro semanas, presentaremos talleres de nuestras nuevas series educativas, que abarcan una gran variedad de temas. Cada serie…
uniQure and CSL Behring recently announced that etranacogene dezaparvovec, an investigational hemophilia B gene therapy currently in clinical trials, has achieved a primary endpoint of “non-inferiority” in annualized bleeding rate (ABR) 18-months…